Wilmin Bartolini

856 total citations
22 papers, 592 citations indexed

About

Wilmin Bartolini is a scholar working on Surgery, Gastroenterology and Molecular Biology. According to data from OpenAlex, Wilmin Bartolini has authored 22 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 10 papers in Gastroenterology and 4 papers in Molecular Biology. Recurrent topics in Wilmin Bartolini's work include Gastrointestinal motility and disorders (9 papers), Helicobacter pylori-related gastroenterology studies (7 papers) and Gastroesophageal reflux and treatments (4 papers). Wilmin Bartolini is often cited by papers focused on Gastrointestinal motility and disorders (9 papers), Helicobacter pylori-related gastroenterology studies (7 papers) and Gastroesophageal reflux and treatments (4 papers). Wilmin Bartolini collaborates with scholars based in United States, Canada and United Kingdom. Wilmin Bartolini's co-authors include Mark G. Currie, Robert Busby, Alexander P. Bryant, Gerhard Hannig, Caroline B. Kurtz, Marco M. Kessler, Jenny Tobin, Robert Solinga, Christine M. Pierce and Shalina Mahajan‐Miklos and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Wilmin Bartolini

18 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wilmin Bartolini United States	9	348	251	154	79	38	22	592
Jenny Tobin United States	7	303 0.9×	230 0.9×	152 1.0×	112 1.4×	22 0.6×	14	551
Elena Atanasova United States	8	189 0.5×	104 0.4×	224 1.5×	97 1.2×	37 1.0×	21	504
Nathalie P. Duroudier United Kingdom	8	194 0.6×	112 0.4×	89 0.6×	148 1.9×	9 0.2×	9	411
Nikita Hanning Belgium	8	181 0.5×	58 0.2×	105 0.7×	86 1.1×	23 0.6×	16	333
Andrea Heldsinger United States	13	73 0.2×	71 0.3×	309 2.0×	86 1.1×	68 1.8×	25	593
Hans Raskov Denmark	8	103 0.3×	49 0.2×	204 1.3×	64 0.8×	10 0.3×	9	461
Toshiaki Nagano Japan	12	58 0.2×	96 0.4×	76 0.5×	78 1.0×	75 2.0×	24	426
Stefano Marconi Italy	12	53 0.2×	79 0.3×	114 0.7×	53 0.7×	68 1.8×	19	556
Rick Tuttle Sweden	7	140 0.4×	78 0.3×	128 0.8×	61 0.8×	145 3.8×	10	405
Matthias Banasch Germany	14	32 0.1×	64 0.3×	144 0.9×	85 1.1×	90 2.4×	22	542

Countries citing papers authored by Wilmin Bartolini

Since Specialization

Citations

This map shows the geographic impact of Wilmin Bartolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilmin Bartolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilmin Bartolini more than expected).

Fields of papers citing papers by Wilmin Bartolini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilmin Bartolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilmin Bartolini. The network helps show where Wilmin Bartolini may publish in the future.

Co-authorship network of co-authors of Wilmin Bartolini

This figure shows the co-authorship network connecting the top 25 collaborators of Wilmin Bartolini. A scholar is included among the top collaborators of Wilmin Bartolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilmin Bartolini. Wilmin Bartolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Haines, Eric, Víctor R. De Jesús, Daniel Hidalgo, et al.. (2026). The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers. Nature Cancer. 7(1). 116–130.

Tolcher, Anthony W., Nehal J. Lakhani, Meredith McKean, et al.. (2025). Abstract CT268: Preliminary results from a first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors. Cancer Research. 85(8_Supplement_2). CT268–CT268.

Aggen, David H., Meredith McKean, Jean Hoffman‐Censits, et al.. (2024). IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.. Journal of Clinical Oncology. 42(16_suppl). 2599–2599.

Brenner, Darren M., Brian E. Lacy, Alexander C. Ford, et al.. (2022). Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials. The American Journal of Gastroenterology. 118(5). 872–879. 5 indexed citations

Aggen, David H., Meredith McKean, Nehal J. Lakhani, et al.. (2022). 661 Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma. Regular and Young Investigator Award Abstracts. A692–A692. 3 indexed citations

Lembo, Anthony, Braden Kuo, Ramesh Boinpally, et al.. (2022). Randomised clinical trial: effects of MD‐7246 on irritable bowel syndrome with diarrhoea. Alimentary Pharmacology & Therapeutics. 57(2). 192–204. 1 indexed citations

Amidon, Benjamin, Wilmin Bartolini, Karen McGovern, et al.. (2022). Abstract 2156: IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway. Cancer Research. 82(12_Supplement). 2156–2156. 14 indexed citations

Brenner, Darren M., Brian E. Lacy, Alexander C. Ford, et al.. (2021). S510 Time to Relief of Key Abdominal and Bowel Symptoms of Irritable Bowel Syndrome with Constipation: A Post-Hoc Analysis of Randomized Controlled Trials of Linaclotide. The American Journal of Gastroenterology. 116(1). S228–S228. 1 indexed citations

Assouline-Dayan, Yehudith, et al.. (2021). A236 LINACLOTIDE IS NOT DETECTABLE IN BREAST MILK OF LACTATING WOMEN: AN OPEN-LABEL, PHASE 1 STUDY. Journal of the Canadian Association of Gastroenterology. 4(Supplement_1). 285–287.

10.

Chang, Lin, Brian E. Lacy, Baha Moshiree, et al.. (2021). Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. The American Journal of Gastroenterology. 116(9). 1929–1937. 32 indexed citations

11.

Chey, William D., Gregory S. Sayuk, Wilmin Bartolini, et al.. (2020). Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation. The American Journal of Gastroenterology. 116(2). 354–361. 17 indexed citations

12.

Nurko, Samuel, Jeffrey S. Hyams, Niels Borgstein, et al.. (2020). 911 LINACLOTIDE SAFETY AND EFFICACY IN CHILDREN AGED 7 TO 17 YEARS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION. Gastroenterology. 158(6). S–182. 1 indexed citations

13.

Busby, Robert, Marco M. Kessler, Wilmin Bartolini, et al.. (2012). Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation. Journal of Pharmacology and Experimental Therapeutics. 344(1). 196–206. 112 indexed citations

14.

Busby, Robert, Alexander P. Bryant, Wilmin Bartolini, et al.. (2010). Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. European Journal of Pharmacology. 649(1-3). 328–335. 175 indexed citations

15.

Johnston, Tom H., Philippe Huot, Susan H. Fox, et al.. (2010). Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics. 336(2). 423–430. 35 indexed citations

16.

Bryant, Alexander P., Robert Busby, Wilmin Bartolini, et al.. (2010). Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sciences. 86(19-20). 760–765. 154 indexed citations

17.

Bartolini, Wilmin & Murray V. Johnston. (2000). Characterizing DNA photo-oxidation reactions by high-resolution mass measurements with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Journal of Mass Spectrometry. 35(3). 408–416. 5 indexed citations

18.

Bartolini, Wilmin, et al.. (1999). Identification of single stranded regions of DNA by enzymatic digestion with matrix-assisted laser desorption/ionization analysis. Journal of the American Society for Mass Spectrometry. 10(6). 521–528. 10 indexed citations

19.

Xirasagar, Sandhya, et al.. (1998). RNA Structure Inhibits the TRAP ( rp RNA-binding AttenuationProtein)-RNA Interaction. Journal of Biological Chemistry. 273(42). 27146–27153. 20 indexed citations

20.

Rouzer, Carol A., et al.. (1993). An unexpected pathway for the metabolic degradation of 1,3-dialkyl-3-acyltriazenes. Biochemical Pharmacology. 46(1). 165–173. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact